Financials

  • Market Capitalization 23.45 M
  • Employee 105
  • Founded 2016
  • CEO N/A
  • Website www.barinthusbio.com
  • Headquarter United Kingdom
  • FIGI BBG00ZZPCP09
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-0.78
Price to sales ratio
3.18
Dividends per share
Dividend yield %

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics plc is a biotechnology company developing immunotherapies for infectious diseases, cancer and autoimmune diseases such as hepatitis B, HPV and prostate cancer. Formerly known as Vaccitech plc, in November 2023 the company announced that it had renamed itself to Barinthus Biotherapeutics plc. As of 2024, the company employs more than 100 people.

ニュース